CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: May 5, 2014
Result type: Reports
Project Number: SR0380-000
Product Line: Reimbursement Review

Generic Name: Tofacitinib

Brand Name: Xeljanz

Manufacturer: Pfizer Canada Inc.

Therapeutic Area: Arthritis, rheumatoid

Indications: Arthritis, Rheumatoid

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: April 17, 2015

Recommendation Type: List with criteria/condition